Highest-materiality recent filing
Q4 revenue $23.7M (down from $24.6M YoY); gross margin 59.7% (up from 57.1%).
Harvard Bioscience shareholders approve 1-for-10 reverse stock split to regain Nasdaq compliance
Stockholders approved reverse stock split at March 6, 2026 special meeting; 27.0M votes for, 678K against.
Harvard Bioscience preliminary Q4 revenue $23.7M, adj EBITDA $3.8M, 27% YoY growth
Preliminary Q4 revenue $23.7M, above guidance midpoint; gross margin 60% at high end of 58-60% range.
Harvard Bioscience to close Holliston facility; expects $4M annual savings from 2028
Closes Holliston, MA plant; moves US production to Minneapolis, MN; some operations to Germany, Sweden, UK.
Enters $40M senior secured credit facility (Term A $10M, Term B $22.5M, Term C $7.5M convertible at $1.00) maturing Dec 17, 2029
HBIO Q3: revenues $20.6M, net loss narrows to $1.2M; Q4 guidance $22.5-$24.5M
Q3 2025 revenues $20.6M (down 6.4% YoY); gross margin 58.4% vs 58.1%.
Harvard Bioscience gets 180-day Nasdaq bid-price extension, transfers to Capital Market
Nasdaq granted until March 30, 2026 to reach $1.00 minimum bid price for 10 consecutive days.
Harvard Bioscience Reports Q2 2025 Revenue of $20.5M, Net Loss of $2.3M, and Credit Amendment
Q2 2025 revenue of $20.5M vs $23.1M in Q2 2024; gross margin 56.4% vs 57.2%.
Harvard Bioscience gets covenant waiver, interest rate jumps to SOFR+700bps; going concern doubt
Waived defaults for failing Q2 2025 financial covenants; no covenant test for Q3 2025.
Harvard Bioscience appoints John Duke as CEO; Q2 revenue anticipated at $20.4M
Jim Green resigns as President & CEO effective July 28, 2025; retirement not due to any disagreement.
Harvard Bioscience Q1 net loss $50.3M includes $48M goodwill impairment; guides Q2 revenue $18-20M
Revenue $21.8M vs $24.5M YoY (-11%); net loss $(50.3)M vs $(4.7)M, including $48.0M goodwill impairment.
Harvard Bioscience receives Nasdaq bid-price deficiency; CFO Cote resigns effective May 12
Nasdaq notified HBIO on April 4, 2025 of non-compliance with $1.00 minimum bid price; 180-day cure through Oct 1, 2025.
Harvard Bioscience enters debt waiver and amendment; substantial doubt about going concern
Fifth Amendment waives default on net leverage ratio covenant as of Dec 31, 2024; covenant testing suspended through March 31, 2025 if milestones met.
Harvard Bioscience Q4 revenue $24.6M, FY 2024 net loss widens to $12.4M
Q4 2024 revenue $24.6M, down 12.8% from $28.2M in Q4 2023.
Harvard Bioscience Q3 revenue falls 13% to $22M; net loss widens to $4.8M
Revenue $22.0M, down 13.4% YoY from $25.4M; gross margin stable at 58.1%.
Harvard Bioscience Q2 revenue $23.1M (-20% YoY); GAAP net loss $2.9M
Q2 revenue $23.1M, down 20% from $28.8M; gross margin 57.2% vs 58.0%.
Harvard Bioscience Q1 revenue falls 18% to $24.5M; posts GAAP net loss of $4.7M
Revenue $24.5M, down 18% YoY from $30.0M; gross margin 60.3% vs 61.2%.
Received $3.1M cash in Q1 2024 from employee retention credits (ERC); expects additional $3.1M in FY2024.
Harvard Bioscience Q4 2023 revenue $28.2M, guides 2024 flat-to-modest growth, margin improvement
Q4 revenue $28.2M, down 1% YoY; gross margin 58.0%, up 230 bps YoY.
Harvard Bioscience prelim FY2023 revenue ~$112.3M; includes $5.1M discontinued product headwind
Preliminary unaudited FY2023 revenue estimate of ~$112.3M, down from $113.3M in FY2022, with $5.1M net headwind from discontinued products.
Harvard Bioscience Q3 revenue $25.4M (-6% YoY); adjusted EBITDA margin 8.9%
Q3 2023 revenues $25.4M vs $26.9M prior year; gross margin improved to 58.1% from 45.2%.
Harvard Bioscience Q2 revenue $28.8M; adj. op. income up to $3.6M; guides FY23 $116-120M
Q2 revenue $28.8M (-1% YoY) as discontinued product headwinds ($1.6M) offset new product growth.
Harvard Bioscience Q1 revenue $30M (+4% YoY); net income $0.6M vs $6.9M loss; adj EBITDA margin 16%
Q1 revenues $30.0M, up 4% from $28.8M in Q1'22; gross margin improved to 61% from 56%.
HBIO Q4 revenue $28.4M (-14% YoY), GAAP net loss $1.7M; guides low-single-digit growth in FY23
Revenues $28.4M, down 14% YoY; negative currency impact of $1.0M.
CFO Michael Rossi resigns from Harvard Bioscience; separation agreement signed
Rossi resigned as CFO and Treasurer effective Dec 31, 2022; remains employee through May 10, 2023 for transition.
Harvard Bioscience Q3 revenue down 9% to $26.9M; GAAP operating loss $3.8M vs income $0.5M
GAAP diluted EPS ($0.08) vs ($0.00); adjusted diluted EPS ($0.01) vs $0.06.
Harvard Bioscience Q2 revenue flat, cuts workforce; guides to 1-5% growth and 13-14% op margin
Q2 revenue flat at $29.2M; GAAP operating income $4.0M includes $4.9M litigation benefit.
On June 10, 2025, Alan Edrick resigned from the board of directors of Harvard Bioscience, Inc. (the “Company”), effective June 10, 2025.
On June 2, 2025, the Board appointed John D. Duke to serve as a member of the Board, June 2, 2025.
On May 30, 2025, Thomas Loewald informed the Company of his resignation from the board of directors (the “Board”) of Harvard Bioscience, Inc. (the “Company”), effective May 30, 2025.
One June 2, 2025, the Board appointed Katherine Eade as the Board’s Lead Independent Director.
On April 10, 2025, Bertrand Loy informed the Company that he will not stand for re-election at the Company’s 2025 Annual Meeting.
On April 10 2025, the Board of Directors of the Company appointed Mark Frost to serve as Interim Chief Financial Officer and Treasurer effective upon Ms. Cote’s resignation (the “Effective Date”).
On April 7, 2025, Jennifer Cote notified the Company of her resignation as Chief Financial Officer and Treasurer.
On June 20, 2023, Harvard Bioscience, Inc. (the “Company”) issued a press release announcing the appointment of Jennifer Cote as the Company’s Chief Financial Officer and Treasurer effective as of June 19, 2023.
On December 7, 2022, Michael Rossi notified Harvard Bioscience, Inc. (the “Company”) of his resignation as the Company’s Chief Financial Officer and Treasurer effective December 31, 2022.
On December 8, 2022, the Company appointed Jennifer Cote to serve as Interim Chief Financial Officer and Treasurer effective upon Mr. Rossi’s resignation.
On December 7, 2022, Michael Rossi notified Harvard Bioscience, Inc. (the “Company”) of his resignation as Chief Financial Officer and Treasurer, effective December 31, 2022.
On January 24, 2022, Harvard Bioscience, Inc. (the “Company”) accepted the resignation of Ken Olson for personal reasons from his position as Chief Operating Officer of the Company effective January 31, 2022.
Max materiality 0.90 · Median 0.60 · Most common event earnings